Literature DB >> 14570293

Anti-Hu paraneoplastic syndrome presenting with brainstem-cerebellar symptoms and Lambert-Eaton myasthenic syndrome.

Toshiko Nagashima1, Yasuyuki Mizutani, Hiromasa Kawahara, Shiro Maguchi, Yoshihiko Terayama, Toshiya Shinohara, Yasuko Orba, Takayo Chuma, Yukio Mano, Tomoo Itoh, Hirofumi Sawa, Koichiro Sakai, Masakatsu Motomura, Kazuo Nagashima.   

Abstract

Paraneoplastic syndrome (PNS) with two distinct neurological features was reported in a 50-year-old man who presented initially with vertigo, ataxia, dysarthria, tremor, confusion, urinary retention and hypotension. Pulmonary X-ray findings, class IIIb sputum cytology, and positive anti-Hu antibody established the diagnosis of PNS associated with small-cell lung cancer (SCLC). Two cycles of combined chemotherapy resulted in shrinkage of the lung tumor together with complete recovery of neurological symptoms and disappearance of anti-Hu antibody. Relapse of SCLC 4 months later with re-appearance of anti-Hu antibody required additional chemotherapy and irradiation. Eight months later, when multiple liver metastasis of SCLC was noticed, muscular weakness with positive waxing phenomenon compatible with Lambert-Eaton myasthenic syndrome (LEMS) developed. Postmortem examinations revealed residual SCLC in the primary lung, and massive liver metastasis with generalized lymph node involvement, but no tumors in the CNS. In the cerebellum, there was a slight loss of Purkinje cells with torpedo formation but without apparent lymphocytic infiltration. The present PNS was unique in that the relapse of SCLC was accompanied by the appearance of anti-Hu antibody, and that initial signs of brainstem-cerebellar symptoms, encephalopathy and autonomic failure were replaced by LEMS coinciding with the tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14570293     DOI: 10.1046/j.1440-1789.2003.00501.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  2 in total

1.  Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.

Authors:  M Hardy-Werbin; O Arpí; A Taus; P Rocha; D Joseph-Pietras; L Nolan; S Danson; R Griffiths; M Lopez-Botet; A Rovira; J Albanell; C H Ottensmeier; E Arriola
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

2.  Relapse of both small cell lung cancer and Lambert-Eaton myasthenic syndrome after a 13-year disease-free survival period.

Authors:  Fumio Asano; Keisuke Watanabe; Masaharu Shinkai; Yoshitaka Tei; Kei Mishina; Mikiko Tanabe; Hiroshi Ishii; Masahiro Shinoda; Tadasuke Shimokawaji; Makoto Kudo; Takeshi Kaneko
Journal:  Chin J Cancer       Date:  2016-07-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.